As demand for GLP‑1 therapies grows in obesity and Type 2 diabetes care, manufacturers must rapidly scale production while meeting strict GMP requirements. This case study shows how Boccard delivered a robust and scalable GLP‑1 production line.

As demand for immunoglobulin therapies grows across rare autoimmune diseases, manufacturers must expand plasma fractionation capacity while maintaining strict GMP and viral safety standards. This case study shows how Boccard delivered a large-scale, integrated immunoglobulin production facility designed to support long-term IVIg supply.